Twist Bioscience Corp (TWST) released Loss for its second quarter of -$44.021 million The company's bottom line totaled -$44.021 million, or -$0.71 per share. This compares with -$39.328 million, or -$0.66 per share, last year. The company's revenue for the period rose 19.3% to $110.715 million...
Mirum Pharmaceuticals, Inc. (MIRM), Monday said that its VISTAS Phase 2b study evaluating Volixibat met primary endpoint in patients with primary sclerosing cholangitis or PSC. The company said the result support the potential for Volixibat as the first treatment for cholestatic pruritus in patients...
MacroGenics, Inc. (MGNX) on Monday said it has entered into an expanded royalty purchase agreement with Sagard Healthcare Partners, under which it will receive funding in exchange for a capped share of future sales of Zynyz. The amended agreement, that builds on an initial deal signed in June 2025,...
Pasithea Therapeutics Corporation (KTTA) said on Monday that it has appointed Kartik Krishnan as chief medical officer with effect from May 1. Krishnan has over 20 years of experience in clinical development, pharmacovigilance, clinical operations, and others. Prior to joining Pasithea, Krishnan...
Vertex Pharmaceuticals Inc. (VRTX) reported a profit for its first quarter that Increases, from last year The company's bottom line came in at $1.031 billion, or $4.02 per share. This compares with $646.3 million, or $2.49 per share, last year. Excluding items, Vertex Pharmaceuticals Inc. reported...
Amgen Inc. (AMGN) Monday revealed its plan to invest an additional $300 million in its U.S. manufacturing network to further advance U.S.-based production capacity. The investment in Juncos, Puerto Rico is expected to enhance next-generation technologies and support a reliable supply of medicines for...
Johnson & Johnson (JNJ) on Monday reported positive results from a network meta-analysis comparing Caplyta with other FDA-approved atypical antipsychotics used as add-on treatments for major depressive disorder in adults. The analysis, based on data from 10 registrational studies, found that Caplyta...
Monday, Takeda Pharmaceutical Company Limited (TAK) announced positive topline data from TAK-881-3001, a pivotal Phase 2/3 clinical trial evaluating TAK-881 in patients with Primary Immunodeficiency Disease or PID. The trial evaluated the pharmacokinetic, efficacy, safety, tolerability and immunogenicity...
Pfizer Inc. (PFE) on Wednesday reported positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO in adults with relapsed or refractory multiple myeloma who had received at least one prior line of treatment. The study met its primary endpoint, showing a statistically significant...
AbbVie Inc. (ABBV) on Tuesday reported positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study, showing that Rinvoq outperformed Humira in treating adults with moderate to severe rheumatoid arthritis. The study met its primary endpoint, with Rinvoq demonstrating superiority over...
Atossa Therapeutics, Inc. (ATOS) on Monday said the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to (Z)-endoxifen for the treatment of McCune-Albright Syndrome in females. McCune-Albright Syndrome is a rare genetic disorder caused by mutations in the GNAS gene,...
The May FDA calendar appears relatively light. The upcoming regulatory milestones include a potential label expansion of argenx SE's VYVGART, and an additional indication for Daiichi Sankyo Company and AstraZeneca plc's cancer therapy Enhertu, among others.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
a2 Milk Company Ltd. (ACOPF, A2M.AX), a dairy company, announced a recall of select infant milk formula, manufactured by Synlait Milk Limited and sold only in the United States, citing the presence of cereulide. The recall involves three batches of a2 Platinum USA label infant milk formula, comprising...
Cytokinetics, Incorporated (CYTK) is preparing to unveil the first topline data from ACACIA-HCM, its pivotal Phase 3 clinical trial evaluating Aficamten in adults with non-obstructive hypertrophic cardiomyopathy (nHCM).
Researchers at APC Microbiome Ireland, based at University College Cork, have made an important discovery about how coffee affects the body. For the first time, they closely studied how coffee, whether or not it contains caffeine, interacts with the 'gut-brain axis,' the system that connects the digestive...
The number of years that people in Britain can expect to live in good health has fallen sharply over the past decade, with more individuals experiencing illness well before reaching retirement age, according to a new study. Between 2012 and 2014 and 2022 and 2024, healthy life expectancy (HLE) in...
Shares of Viemed Healthcare Inc. (VMD), a provider of home medical equipment and post-acute healthcare services in the United States, touched a new 52-week high of $10.10 during intraday trading yesterday. The company's sustained financial performance, combined with multiple growth engines, makes it a compelling long-term stock to watch.